Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Intensive screening for osteoporosis in patients with hip fracture

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Does vascular endothelial dysfunction play a role in physical frailty and sarcopenia? A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. RANKL regulates male reproductive function

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The calcium-sensing receptor is essential for calcium and bicarbonate sensitivity in human spermatozoa

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Elaine M Dennison
  • Katrine Hass Rubin
  • Peter Schwarz
  • Nicholas C Harvey
  • Karen Walker Bone
  • Cyrus Cooper
  • Bo Abrahamsen
View graph of relations

UNLABELLED: Using a Danish Register cohort of 86,039 adult new allopurinol users and propensity score matched controls, we found that gout requiring allopurinol prescription was associated with an increased fracture risk.

PURPOSE: Gout, an acute inflammatory arthritis, is common and associated with elevated serum urate, obesity and high alcohol consumption. The mainstay of therapy is the urate-lowering agent, allopurinol. Here, we report the relationship between allopurinol prescription and fracture in a large registry population.

METHODS: We established a Danish Register cohort of 86,039 adult cases (new allopurinol users) and 86,039 age, sex and propensity score matched controls (not exposed to allopurinol or with a gout diagnosis), with no diagnosis of malignancy in the year prior.

RESULTS: We found a modest adjusted effect of allopurinol prescription on major osteoporotic fractures (hazard ratio (HR) 1.09, 95 % confidence interval (CI) 1.05-1.14, p = 0.04) and on hip fractures (HR 1.07, 95 % CI 1.11-1.14, p < 0.001), robust to adjustment for confounding factors (age, sex, comorbidity, medication use). Associations were stronger in men than women, and among incident allopurinol users whose gout diagnosis had been confirmed by at least one hospital contact. Prespecified subanalyses by filled dose of allopurinol (mg/day in first year of prescription) showed increased hip and major fracture risk in women in the highest allopurinol dose grouping only, while a less strong dose effect was evident for fracture rates in men.

CONCLUSION: Gouty arthritis requiring allopurinol is associated with an excess risk of major or hip fracture, with an allopurinol dose effect evident in women such that women taking the highest doses of allopurinol--suggestive of more severe disease--were at increased risk relative to women taking lower doses.

Original languageEnglish
JournalArchives of Osteoporosis
Volume10
Pages (from-to)36
ISSN1862-3522
DOIs
Publication statusPublished - 2015

ID: 46169786